Rennova Health (RNVA) 10-Q2015 Q3 Quarterly report

Filed: 13 Feb 15, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: annum, bid, blood, borrowed, Bulletin, coincident, consummated, covenant, default, diligence, explanatory, fee, fifteen, hearing, inclusion, insufficient, intent, issuable, letter, Medytox, monitoring, notified, Notwithstanding, occurrence, ourcommon, pain, Panel, par, paragraph, percent, printer, provision, rank, regain, rehabilitation, reliant, representation, request, requested, scheduled, sector, SecurityAgreement, simple, Solutionswould, sought, toxicology, unexercised, urine, warranty

Removed: account, adjustment, annotate, April, automatically, bankruptcy, collectibility, conform, controlling, convert, cumulative, define, deprive, Derecognition, disagree, disallowance, discount, dissolve, earlier, Emerging, exhibit, extraordinary, initiative, integrate, liquidate, marginally, parent, Participating, proceeding, prospectively, reclassified, resided, settle, submit, Task, translation, vote, wave

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

RNVA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of CollabRx, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended December 31, 2014 as filed with the Securities and Exchange Commission (the “Report”), I, Thomas R. Mika, President and Chief Executive Officer of the Company, certify, pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Sec. 1350), that to my knowledge:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/Thomas R. Mika
President and Chief Executive Officer
February 13, 2015

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of CollabRx, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended December 31, 2014 as filed with the Securities and Exchange Commission (the “Report”), I, Thomas R. Mika, Acting Chief Financial Officer of the Company, certify, pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Sec. 1350), that to my knowledge:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Thomas R. Mika
Acting Chief Financial Officer
February 13, 2015

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.